BR112017020178A2 - vacina estreptocócica - Google Patents

vacina estreptocócica

Info

Publication number
BR112017020178A2
BR112017020178A2 BR112017020178A BR112017020178A BR112017020178A2 BR 112017020178 A2 BR112017020178 A2 BR 112017020178A2 BR 112017020178 A BR112017020178 A BR 112017020178A BR 112017020178 A BR112017020178 A BR 112017020178A BR 112017020178 A2 BR112017020178 A2 BR 112017020178A2
Authority
BR
Brazil
Prior art keywords
streptococcal vaccine
streptococcal
vaccine
methods
relates
Prior art date
Application number
BR112017020178A
Other languages
English (en)
Inventor
David Ogunniyi Abiodun
Yannis Chen Austen
Cleland Paton James
Alsharifi Mohammed
Babb Rachelle
Christa David Shannon
Raymond Hirst Timothy
Original Assignee
Gpn Vaccines Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015901098A external-priority patent/AU2015901098A0/en
Application filed by Gpn Vaccines Pty Ltd filed Critical Gpn Vaccines Pty Ltd
Publication of BR112017020178A2 publication Critical patent/BR112017020178A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

a presente invenção refere-se a preparações de vacina estreptocócicas irradiadas com fótons e métodos para seu uso.
BR112017020178A 2015-03-26 2016-03-24 vacina estreptocócica BR112017020178A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015901098A AU2015901098A0 (en) 2015-03-26 Streptococcal vaccine
PCT/AU2016/050231 WO2016149771A1 (en) 2015-03-26 2016-03-24 Streptococcal vaccine

Publications (1)

Publication Number Publication Date
BR112017020178A2 true BR112017020178A2 (pt) 2018-06-12

Family

ID=56976886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020178A BR112017020178A2 (pt) 2015-03-26 2016-03-24 vacina estreptocócica

Country Status (11)

Country Link
US (2) US10821168B2 (pt)
EP (1) EP3273989B1 (pt)
JP (2) JP6903046B2 (pt)
CN (2) CN107427569B (pt)
AU (1) AU2016236770B2 (pt)
BR (1) BR112017020178A2 (pt)
CA (1) CA2980616A1 (pt)
ES (1) ES2970824T3 (pt)
MY (1) MY191539A (pt)
SG (1) SG11201707926WA (pt)
WO (1) WO2016149771A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980616A1 (en) * 2015-03-26 2016-09-29 Gpn Vaccines Pty Ltd Streptococcal vaccine
CN108884134A (zh) * 2015-12-10 2018-11-23 加拿大全国研究委员会 脂化肺炎链球菌抗原组合物、制备方法和用途
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
US20200330579A1 (en) * 2017-10-04 2020-10-22 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
CN113395980B (zh) 2019-01-08 2023-09-15 韩国原子力研究院 利用放射线制备减毒活疫苗的方法及通过其制备的减毒活疫苗组合物
KR20200097134A (ko) * 2019-02-07 2020-08-18 에스케이바이오사이언스(주) 교차반응이 없는 폐렴구균 항혈청 및 이의 제조방법
US20210361757A1 (en) * 2020-05-22 2021-11-25 GPN Vaccines Ltd Streptococcal vaccine formulations and uses thereof
US20210361758A1 (en) * 2020-05-22 2021-11-25 GPN Vaccines Ltd Streptococcal vaccines and methods for use
CN113005072A (zh) * 2021-04-09 2021-06-22 佛山科学技术学院 一种马链球菌兽疫亚种基因缺失株及其制备方法和应用
CN117159480B (zh) * 2023-11-01 2024-03-01 江西赛基生物技术有限公司 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567938A (en) 1968-02-14 1971-03-02 Credo Inc Gamma ray laser
US3557370A (en) 1968-02-14 1971-01-19 Dawson Inc Alexander Gamma ray laser having a low temperature closed resonating cavity
CA2030551C (en) 1989-05-01 1998-08-25 Wayne Gombotz Process for producing small particles of biologically active molecules
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AU2004294732B2 (en) * 2003-12-03 2009-10-08 Intervet International B.V. Streptococcus phocae vaccine
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
EP3020411A1 (en) * 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
EA201001479A1 (ru) * 2008-04-16 2011-06-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
EP2667891B1 (en) * 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
BR112013026929A2 (pt) 2011-04-20 2016-12-27 Mico Bio Inc composição e método para intensificação de uma resposta imune
JP6382936B2 (ja) * 2013-03-14 2018-08-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ナノ粒子ベースの組成物
CA2980616A1 (en) 2015-03-26 2016-09-29 Gpn Vaccines Pty Ltd Streptococcal vaccine

Also Published As

Publication number Publication date
EP3273989A1 (en) 2018-01-31
CN116603058A (zh) 2023-08-18
EP3273989B1 (en) 2023-12-27
EP3273989A4 (en) 2018-08-08
CN107427569B (zh) 2022-12-30
KR20170129786A (ko) 2017-11-27
AU2016236770B2 (en) 2022-03-10
CN107427569A (zh) 2017-12-01
ES2970824T3 (es) 2024-05-30
JP6903046B2 (ja) 2021-07-14
WO2016149771A1 (en) 2016-09-29
CA2980616A1 (en) 2016-09-29
SG11201707926WA (en) 2017-10-30
AU2016236770A1 (en) 2017-10-12
US11235048B2 (en) 2022-02-01
MY191539A (en) 2022-06-30
US20180117136A1 (en) 2018-05-03
JP2021138781A (ja) 2021-09-16
JP2018513877A (ja) 2018-05-31
US10821168B2 (en) 2020-11-03
US20210170011A1 (en) 2021-06-10
JP7269281B2 (ja) 2023-05-08
EP3273989C0 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
BR112017020178A2 (pt) vacina estreptocócica
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112018072587A2 (pt) neurotoxinas quiméricas
NI201700019A (es) Anticuerpos anti tigit
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
BR112018008901A2 (pt) formulações subcutâneas de anticorpos anti-cd 38 e seus usos
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
BR112015032224A2 (pt) anticorpos anti-fcrh5
AR095233A1 (es) Métodos y composiciones para el control de malezas
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
BR112018010102A2 (pt) conjugados farmacêuticos de anticorpos sítio-específicos para her2
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/03/2016, OBSERVADAS AS CONDICOES LEGAIS